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Learning the hard way: clinical trials in 
juvenile idiopathic arthritis
Roberta A Berard,1 Ronald M Laxer2
There have been unprecedented advances 
in the treatments and outcomes reported 
for patients living with juvenile idiopathic 
arthritis (JIA) over the last 20 years. The 
future direction of care with multinational 
collaborations (Paediatric Rheumatology 
International Trials Organisation 
(PRINTO), Pediatric Rheumatology 
Collaborative Study Group (PRCSG), 
Childhood Arthritis and Rheumatology 
Research Alliance) and advances in preci-
sion medicine will undoubtedly continue 
to revolutionise our approach to diag-
nosis, treatment and perhaps ultimately 
cure of JIA. In Annals of the Rheumatic 
Diseases, Brunner et al report on the use 
of subcutaneous golimumab for children 
with active polyarticular course JIA.1 This 
trial, no doubt associated with immense 
direct and indirect costs, produced nega-
tive results, as it did not achieve its primary 
end point. Despite this, there is wide-
spread international opinion that golim-
umab, like other tumour necrosis factor 
(TNF) inhibitors, is effective and should 
be added to the therapeutic armamen-
tarium for children with JIA. We must 
reflect on this outcome as we consider 
further studies with new agents in the 
treatment of children with JIA.
To date, three trials of anti-TNF agents 
(etanercept, infliximab and adalimumab),2–4 
one of a selective T cell costimulation 
modulator (abatacept),5 and an inter-
leukin-6 receptor inhibitor6 (tocilizumab) 
have shown efficacy and safety in the treat-
ment of polyarticular course JIA in spite of 
the fact that primary end point of efficacy 
was not met in the infliximab trial. Amar-
ilyo et al7 published a meta-analysis of 
randomised withdrawal trials which eval-
uated the five separate trials (abatacept,5 
adalimumab,8 anakinra,9 etanercept10 and 
tocilizumab6) all versus placebo. There were 
no statistical differences among biological 
agents for efficacy or safety. The parallel 
design infliximab trial published in 2007 
failed to meet the primary efficacy end 
point of American College of Rheuma-
tology Pediatric 30 Criteria (ACRPed30) 
at week 14 of infliximab (3 mg/kg) versus 
placebo.3 Several factors including inade-
quate infliximab dosing, too brief placebo 
treatment phase and higher-than-expected 
placebo-response rate may have contrib-
uted to these negative results. Concerns 
regarding this study, some of which we raise 
again 10 years later, were addressed in an 
accompanying editorial.11 Subsequently, 
infliximab monotherapy was shown to be 
effective in the aggressive combination drug 
therapy in very early polyarticular juvenile 
idiopathic arthritis (ACUTE-JIA trial),12 a 
randomised open-label trial that compared 
methotrexate, methotrexate/sulfasalazine/
hydroxychloroquine (COMBO) and inflix-
imab (3–5 mg/kg) in disease-modifying 
antirheumatic drug-naive patients. At week 
54, ACRPed75 was achieved in 100% on 
infliximab, 65% on COMBO and 50% on 
methotrexate monotherapy, p<0.0001. 
Furthermore, patients on infliximab 
remained in a state of inactive disease for a 
longer duration (6 months) than the other 
two treatment arms (3 months for COMBO 
and 1 month for methotrexate). Despite the 
initial negative trial, infliximab continues to 
be used in clinical practice with effective-
ness reported similar to the other biological 
agents.13
There are inherent challenges in the 
study of treatment efficacy in children 
and in particular concerning rare diseases 
such as JIA.11 14–16 There are requirements 
from the medical community, pharmaceu-
tical industry and regulatory agencies that 
have an ethical responsibility to design, 
conduct and report on high-quality studies 
of medicines in children. To minimise the 
number of children exposed to placebo 
while providing adequate recruitment, 
the three-part placebo-controlled, double-
blind, randomised withdrawal design17 
has been used in several trials in patients 
with JIA. This trial design tends to over-
estimate the effect of the trial agent, as 
only those who have an initial response 
proceed to the blinded withdrawal phase. 
Theoretically, this design should be limited 
to drugs with short half-lives that will not 
lead to carry-over effects; otherwise the 
time of the second phase would need to 
be increased, thus negating the benefit of 
this trial design.
In the current golimumab study, 
members of PRINTO and PRCSG report 
on the use of golimumab in polyarticular 
course JIA resistant to treatment with meth-
otrexate.1 The study involved 33 sites in 
12 countries for a total enrolment of 173 
patients. Similar to the etanercept, adalim-
umab, abatacept and tocilizumab trials, the 
study was a randomised withdrawal trial 
with the primary outcome defined as JIA 
flares in the withdrawal phase. Secondary 
outcomes included ACRPed50/70/90 
responses, clinical remission, pharmacoki-
netics and safety. In the open-label phase, 
89%/79.2%/65.9%/36.4% demonstrated 
an ACRPed30/50/70/90 response. At the 
end of phase II (week 48) the primary end 
point was not met (JIA flares, golimumab 
vs placebo: 32/78=41% vs 36/76=47%; 
p=0.41).
It is important to consider the reasons 
why this trial might not have met its 
primary end point. One can postulate on 
the possible factors contributing to the 
negative results. (1) The long half-life of 
golimumab could have led to carry-over 
effects in the randomised withdrawal 
phase. (2) Disease duration at time of 
initiation of golimumab as well as dura-
tion and dosing of methotrexate may have 
had a differential impact on response to 
therapy.12 18 The eligibility criteria speci-
fied disease duration of at least 6 months 
but disease duration at baseline was not 
collected; the proportion of patients on 
a dose of 15 mg/m2 subcutaneous meth-
otrexate was not provided. (3) The pres-
ence of neutralising antibodies could have 
had an effect on efficacy (the number 
of patients with high titre neutralising 
antibodies was small (n=8) in this study 
precluding definitive assessment of the 
clinical impact). The other main biolog-
ical trials2–6 similarly report low preva-
lence and generally low titre neutralising 
antibodies, but there are issues with the 
timing of testing, reliability of the assays 
and generalisability of the results. The 
prevalence and potential clinical signifi-
cance of antidrug antibodies in primary 
and secondary treatment failure to biolog-
ical agents in paediatric rheumatology 
warrants further investigation.
There are no doubt differences in the 
pathogenesis of rheumatoid arthritis (RA) 
and JIA, at minimum as evidenced by 
the absence of circulating autoantibodies 
(rheumatoid factor and anti-cyclic-citrulli-
nated peptide(CCP)) in most cases as well 
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as the presence of chronic anterior uveitis; 
however, there has yet to be a biological 
agent that has proven to be ineffective for 
use in JIA once its effect has been demon-
strated in RA. Similarly, biological agents 
found to be effective in the adult spondy-
loarthropathies have been successful in the 
paediatric population with enthesitis-re-
lated arthritis,19 20 a forerunner to spondy-
loarthropathy in later years. Furthermore, 
biological agents effective in systemic JIA 
have been used successfully in adult-onset 
Still’s disease, likely the same disease differ-
entiated essentially by the age of onset.
As highlighted, there are many chal-
lenges in conducting typical randomised 
controlled trials in paediatric patients 
including ethics, acceptability, diffi-
culty in recruiting an adequate sample 
size, rarity of disease and standardisa-
tion (age, outcome measures, selective 
reporting) and alternate trial designs are 
not without challenges. It may be time 
to rethink the regulatory approach to 
approvals of biological agents that have 
been documented to be effective in the 
adult population. At a minimum, perhaps 
approval of a new biological agent for 
non-systemic polyarticular course JIA 
(that already has proven efficacy in RA) 
should only require paediatric trials of 
pharmacokinetic and safety to save the 
time and expense of a clinical trial only 
to have it fail. Alternatively, perhaps, as 
shown in systemic JIA,21 the randomised 
placebo-controlled trial with early escape 
should again be considered. Either 
approach will save significant resources 
and allow patients to get the treatment 
they need in a more expeditious way.
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